UECKER DARRIN 4

What Happened
Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences (PLSE), received an award of 100,000 restricted stock units (RSUs) on March 23, 2026. The grant is reported at $0.00 per unit (no cash paid at grant); these are derivative awards that represent the right to receive one share of common stock at vesting. This is an award/grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-03-23; Form 4 filed: 2026-04-03 (filed late relative to the typical 2-business-day rule).
• Transaction type/code: A (award/grant of derivative securities).
• Amount: 100,000 RSUs; reported grant price: $0.00 (no immediate cash consideration).
• Vesting: RSUs will fully vest on March 23, 2029, subject to continued service through that date (see footnote).
• Footnotes from filing: F1 — each RSU equals a contingent right to one share; F2 — full vesting on 3/23/2029, subject to continued service.
• Shares owned after transaction: not reported in this filing.

Context
RSUs are a form of compensation that convert into actual shares only if and when they vest; they do not represent immediate share ownership or a market purchase/sale. Because the filing was submitted 11 days after the reported grant date, it was late under the usual two-business-day Form 4 reporting timeline, which reduces the timeliness of public disclosure (filings late for inadvertence are common but should be noted).